A cinetobacter baumannii is one of the most antibiotic-resistant pathogens encountered in clinical medicine. National surveillance data confirm that 50% of A. baumannii isolates from U.S. ICUs are carbapenem resistant, far higher than for other pathogens, including Pseudomonas aeruginosa (20%) or Klebsiella pneumoniae (10%) (1) . The vast majority of these carbapenem-resistant strains are extreme drug resistant (XDR), defined as resistant to all antibiotics except colistin and tigecycline (2) . Bacteremia and ventilator-associated pneumonia caused by XDR A. baumannii result in 50% mortality rates (3) (4) (5) (6) (7) . Multiple retrospective studies establish that it is the carbapenem resistance that drives remarkably higher mortality (e.g., three-to four-fold increased) during A. baumannii bacteremia and pneumonia, both by increasing the frequency with which inactive empiric therapy is begun and by eliminating highly effective definitive therapy, leaving only suboptimal agents available (8) (9) (10) (11) (12) (13) (14) (15) (16) . Overall, approximately 75,000 cases of XDR A. baumannii infections occur annually in world, resulting in 30,000 excess deaths and excess healthcare costs of $742 million compared with infections caused by susceptible strains (17) . Clearly, new treatment strategies are needed.
New antibiotics targeting Gram-negative bacilli have become available. Unfortunately, of the two such antibiotics recently approved by the U.S. Food and Drug Administration (FDA), ceftolozane-tazobactam has no reliable activity against A. baumannii and ceftazidime-avibactam has activity similar to ceftazidime alone against A. baumannii. Eravacycline may soon be approved by the FDA and does have in vitro activity against A. baumannii. It is likely that its in vivo efficacy will be similar to minocycline or tigecycline for such infections.
In the absence of newly emerging antibacterial agents that are superior to currently available options against XDR A. baumannii, one strategy that has been explored is combination therapy to improve outcomes. The therapeutic combination that has been tested most commonly is colistin and rifampin. While earlier, small studies were promising, a recent, multicenter, randomized trial found no mortality benefit of colistin and rifampin versus colistin alone for the treatment of XDR A. baumannii infections (18) . The other major combination regimens that have been tested include colistin and either tigecycline or carbapenem therapy, the latter based on in vitro evidence of synergy even for carbapenem-resistant strains (19) . Limited data have suggested that the colistin and carbapenem combination therapy may improve outcomes of XDR A. baumannii infections (19, 20) . However, as the use of colistin and rifampin demonstrates, larger scale validation of these results is required. The execution of these trials is urgent, given the outcomes of the infections treated with monotherapy.
In this issue of Critical Care Medicine, Cheng et al (21) attempt to shed light on this question by providing us with the results of a retrospective evaluation of 55 patients with XDR A. baumannii bacteremia treated with either colistin and carbapenem or colistin and tigecycline combination therapy (22) . The investigators found a nonsignificant trend to higher 14-day mortality with colistin and tigecycline compared with colistin and carbapenem therapy (35% vs 15%; p = 0.1) and a strong trend to increased recurrence of bacteremia in the face of ongoing therapy with colistin and tigecycline (18% vs 0%; p = 0.06). By multivariate analysis, patients infected with XDR A. baumannii strains with tigecycline minimum inhibitory concentrations (MICs) of at least 2 μg/mL had a nearly seven-fold higher risk of 14-day mortality if they were treated with colistin and tigecycline than colistin and carbapenem (p = 0.0009). These results suggest that the two combination regimens are similar in efficacy if the bacterial strain's tigecycline MIC is less than 2 μg/ mL, but that the colistin and tigecycline combination is inferior in efficacy if the strain's tigecycline MIC is at least 2 μg/mL.
These data are concordant with a recent study by Chuang et al (11) who found that monotherapy with tigecycline resulted in higher mortality in patients with pneumonia caused by A. baumannii strains with tigecycline MICs of at least 2 μg/mL. Thus, we have clinical validation that the tigecycline breakpoint of at least 2 μg/mL indicates resistance for A. baumannii in both the blood and the lung. Higher mortality results when bacteremia or pneumonia caused by such strains is treated with tigecycline, whether as monotherapy or part of a combination regimen.
There are limitations of the study by Cheng et al (21) . Of primary importance, the study is retrospective and thus hypothesis generating rather than hypothesis confirming. It is also small and underpowered, which likely accounts for the lack of significance in the primary comparison of survival between the two combination regimens. Furthermore, outcomes described for patients treated with monotherapy are not known and were not compared to either combination regimen. Finally, although the study illuminates the relevance of the tigecycline MIC breakpoint for A. baumannii, data are not available for carbapenem MICs. For example, does the current carbapenem breakpoint predict failure with monotherapy carbapenem? And does combination therapy with colistin plus carbapenem result in different outcomes depending on the carbapenem MIC, as was found with tigecycline? Further study with larger datasets, and ideally with prospective design, is required to clarify these questions.
In the meantime, even though the available data are hypothesis generating, the outcomes of XDR A. baumannii are sufficiently bad, and studies are hard enough to conduct that these data are actionable. We can safely conclude that it is imprudent to use tigecycline-based combination regimens to treat patients infected with strains of A. baumannii with tigecycline MICs of at least 2 μg/mL. And monotherapy tigecycline most certainly should not be used to treat such patients.
A. baumannii is a remarkable foe. The current data underscore the ability of Acinetobacter species to recrudesce even after initial clearance from blood and its capacity to develop resistance in the middle of the course of therapy. Our therapeutic armamentarium for XDR A. baumannii infections is limited and is likely to remain so for the foreseeable future. These data provide us some guidance as to how to treat such infections. However, we have a long way to go, and much to learn, to improve outcomes further. We are still at the beginning of exploring the impact of combination therapy on outcomes from these infections. We have learned what combination regimens not to use. But we do not yet know which ones to use-that is, which ones result in superior outcomes compared with monotherapy. We need prospective studies to answer this question and to make combination therapy ready for prime time.
